Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Response Rate to the 3rd and 4th Doses of BNT162b2 Vaccine in Cancer Patients Administered with Active Anti-Neoplastic Treatments

Abed Agbarya
* ORCID logo ,
Ina Sarel
,
Tomer Ziv-Baran
,
Orna Schwartz
,
Mohammad Sheikh-Ahmad
,
Leonard Saiegh
ORCID logo ,
Forat Swaid
* ,
Yelena Shechtman
,
Ella Kozlener
,
Rasha Khoury
,
Urska Janzic
ORCID logo ,
Asala Abu-Ahmad
,
Ronen Brenner
Version 1 : Received: 28 August 2023 / Approved: 28 August 2023 / Online: 29 August 2023 (03:49:55 CEST)

A peer-reviewed article of this Preprint also exists.

Agbarya, A.; Sarel, I.; Ziv-Baran, T.; Schwartz, O.; Shechtman, Y.; Kozlener, E.; Khoury, R.; Sheikh-Ahmad, M.; Saiegh, L.; Swaid, F.; Ahmad, A.A.; Janzic, U.; Brenner, R. Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients undergoing Active Anti-Neoplastic Treatments. Diseases 2023, 11, 128. Agbarya, A.; Sarel, I.; Ziv-Baran, T.; Schwartz, O.; Shechtman, Y.; Kozlener, E.; Khoury, R.; Sheikh-Ahmad, M.; Saiegh, L.; Swaid, F.; Ahmad, A.A.; Janzic, U.; Brenner, R. Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients undergoing Active Anti-Neoplastic Treatments. Diseases 2023, 11, 128.

Abstract

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response of administering the 3rd and 4th vaccine doses to can-cer patients receiving active anti-neoplastic treatment. 142 patients have received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients have received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients after three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients after two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38-42.12), p=0.02 and 17.15 (95% CI 5.01-58.7), p<0.01, respective-ly). Unlike the response after two doses, the 3rd and 4th BNT162b2 vaccine booster doses, had an increased efficacy of 95-100% in cancer patients while on active treatment. This result could be explained by different mechanisms including the development of memory B cells.

Keywords

SARS-CoV-2; BNT162b2 vaccine; cancer patients; anti-neoplastic treatment; chemotherapy; antibodies; immunogenicity.

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.